Screening and detecting counterfeit biologics drugs
Posted on February 26, 2013
By: Ravi Kalyanaraman, Principal Scientist, Bristol-Myers Squibb; Mitesh Chauhan, Research Associate, Norwich Pharmaceutical Inc; Clemonne John Madarang, Product Analyst, Petron Corporation; Michael Ribick, Department Director, Bristol-Myers Squibb; George Dobler, Associate Director of Analytical Technology, Bristol-Myers Squibb.
Introduction Counterfeit drugs pose a significant and fast-growing threat to public health and safety. It has become a major issue for the pharmaceutical industry in the past decade and has placed a significant pressure globally on supply chain integrity1. The recent incident of counterfeit Avastin...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
biosimilar, counterfeit, FDA, handheld Raman, lyophilised cake, Near-Infrared (NIR) spectroscopy, Principal Component Analysis (PCA), Raman, Spectral Match Correlation, World Health Organization (WHO)
Related Product Videos
Portable Analytical Instruments - Thermo Scientific
Related Products
Portable Analytical Instruments - Thermo ScientificSubscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
